Logo

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

Share this

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

Shots:

  • BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia
  • The company also reported that EMA has begun validation of MAA for the therapy on 13 Aug- 2020
  • Vosoritide is an investigational- once-daily injection analog of C-type Natriuretic Peptide (CNP) and is potentially the first treatment for achondroplasia in the US

­ Ref: Biomarin | Image: Fierce Biotech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions